Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia

Current Opinion in Hematology

Volumn 20, Issue 2, 2013, Pages 137-143

  Klimek, Virginia M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

leukemia; myelodysplastic syndromes; therapy related

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; K RAS PROTEIN; LENALIDOMIDE; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME 5; CHROMOSOME 7; CLINICAL DECISION MAKING; COMORBIDITY; CYTOGENETICS; DISEASE FREE SURVIVAL; DOUBLE STRANDED DNA BREAK; DRUG MEGADOSE; GENETIC RISK; HUMAN; MAINTENANCE THERAPY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THERAPY RELATED ACUTE GRANULOCYTIC LEUKEMIA; THERAPY RELATED MYELODYSPLASTIC SYNDROME; TREATMENT OUTCOME; TREATMENT RESPONSE;

BONE MARROW TRANSPLANTATION; DRUG THERAPY; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RISK FACTORS;

EID: 84873409541     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32835d82e6     Document Type: Review

References (34)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer (IARC); 2008. pp. 127-129.
2. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008; 35:418-429.
3. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nature reviews. Cancer 2005; 5:943-955.
4. Pedersen-Bjergaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007:392-397.
5. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364:2496-2506.
6. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64-69.
7. Shih AH, Chung SS, Dolezal EK, et al. Mutational analysis of therapy-related MDS/AML. ASH Annual Meeting Abstracts 2011; 118:2802.
8. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nature Rev Cancer 2012; 12:599-612.
9. Voso MT, Fabiani E, Fianchi L, et al. Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia 2012. doi: 10.1038/leu.2012.267. [Epub ahead of print].
10. Kosmider O, Delabesse E, de Mas VM, et al. TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica 2011; 96:1059-1063.
11. Fried I, Bodner C, Pichler MM, et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica 2012; 97:246-250.
12. Pichler MM, Bodner C, Fischer C, et al. Evaluation of mutations in the isocitrate dehydrogenase genes in therapy-related and secondary acute myeloid leukaemia identifies a patient with clonal evolution to IDH2 R172K homozygosity due to uniparental disomy. Br J Haematol 2011; 152:669-672.
13. Andersen MT, Andersen MK, Christiansen DH, Pedersen-Bjergaard J. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features. Leukemia 2008; 22:951-955.
14. Bains A, Luthra R, Medeiros LJ, Zuo Z. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 2011; 135:62-69.
15. Klimek VM, Dolezal EK, Tees MT, et al. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. Leuk Res 2012; 36:1093-1097.
16. Fianchi L, Criscuolo M, Lunghi M, et al. Outcome of therapy-related myeloid neoplasms treated with azacitidine. J Hematol Oncol 2012; 5:44.
17. Kern W, Haferlach T, Schnittger S, et al. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004; 22:2510-2511.
18. Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117:2137-2145.
19. Godley LA, Njiaju UO, Green M, et al. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma 2010; 51:995-1006.
20. Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapyrelated myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115:1850-1857.
21. Krö ger N, Brand R, van Biezen A, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009; 94:542-549.
22. Armand P, Deeg HJ, Kim HT, et al. Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant 2010; 45:877-885.
23. Chang C, Storer BE, Scott BL, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110:1379-1387.
24. Armand P, Kim HT, Mayer E, et al. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant 2010; 45:1611-1617.
25. Spina F, Alessandrino PE, Milani R, et al. Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. Leuk Lymphoma 2012; 53:96-102.
26. QuintAs-Cardama A, Kim H, Shan J, et al. A prognostic model of therapyrelated myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. ASH Annual Meeting Abstracts 2011; 118:967.
27. Singh ZN, Huo D, Anastasi J, et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007; 127:197-205.
28. Bacher U, Haferlach C, Alpermann T, et al. Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma 2012. [Epub ahead of print].
29. Duffield AS, Aoki J, Levis M, et al. Clinical and pathologic features of secondary acute promyelocytic leukemia. Am J Clin Pathol 2012; 137:395-402.
30. Larson RA, Le Beau MM. Prognosis and therapy when acute promyelocytic leukemia and other 'good risk' acute myeloid leukemias occur as a therapy-related myeloid neoplasm. Mediterr J Hematol Infect Dis 2012; 3:e2011032.
31. Gustafson SA, Lin P, Chen SS, et al. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol 2009; 131:647-655.
32. Ottone T, Cicconi L, Hasan SK, et al. Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia. Leuk Res 2012; 36:474-478.
33. Elliott MA, Letendre L, Tefferi A, et al. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. Eur J Haematol 2012; 88:237-243.
34. Nardi V, Winkfield KM, Ok CY, et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012; 30:2340-2347.